Cross-Sector entity
All 2 tracked stories fall under one category: funding. Axios is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Astromech appears in 2 tracked Cross-Sector stories from July 21, 2026. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: funding. Axios is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Astromech appears in 2 tracked Cross-Sector stories from July 21, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Astromech. Shared-story counts are live from our verified record — not editorial picks.
Funding talks reported at $20B–$30B valuation
Axios and TechCrunch report Colossal is in discussions to raise new capital at a valuation between $20 billion and $30 billion.
Tasmanian devil cancer partnership launched
Colossal Foundation partners with University of Tasmania to combat contagious facial cancer in Tasmanian devils.
Artificial womb tech expected ready in 2027
CEO Ben Lamm tells Rolling Stone the technology could be spun off for human fertility applications.
Bluebuck antelope added as sixth target species
Colossal expands de-extinction pipeline to include bluebuck antelope.
Astromech spinout achieves $2B valuation
AI-driven biology predictive modeling company reaches unicorn status just months after launch.
Colossal valued at $10.2B after dire wolf project reveal
Investors justify valuation based on broad technology platform, not just de-extinction.
Venture capital’s most audacious bet, Colossal Biosciences, is seeking a valuation of $20–$30 billion — a nearly 3x jump — as it generates revenue, spins out high-value startups, and turns its de-extinction mission into a startup factory with government clients and AI-driven assets.
Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
Source: TechCrunch · Marina Temkin (us)
